Please use this identifier to cite or link to this item: http://repositorio.ufla.br/jspui/handle/1/41719
metadata.artigo.dc.title: Low dose anti-inflammatory radiotherapy for the treatment of pneumonia by covid-19: a proposal for a multi-centric prospective trial
metadata.artigo.dc.creator: Algara, M.
Arenas, M.
Marin, J.
Vallverdu, I.
Fernandez-Letón, P.
Villar, J.
Fabrer, G.
Rubio, C.
Montero, A.
metadata.artigo.dc.subject: COVID-19
Radiotherapy
Pneumonia
metadata.artigo.dc.publisher: Elsevier
metadata.artigo.dc.date.issued: Sep-2020
metadata.artigo.dc.identifier.citation: ALGARA, M. et al. Low dose anti-inflammatory radiotherapy for the treatment of pneumonia by covid-19: a proposal for a multi-centric prospective trial. Clinical and Translational Radiation Oncology, [S.l.], v. 24, p. 29-33, Sept. 2020.
metadata.artigo.dc.description.abstract: Background COVID-19 is a highly contagious viral infection with high morbidity that is draining health resources. The biggest complication is pneumonia, which has a serious inflammatory component, with no standardized treatment. Low-dose radiation therapy (LD-RT) is non-invasive and has anti-inflammatory effects that can interfere with the inflammatory cascade, thus reducing the severity of associated cytokine release and might be useful in the treatment of respiratory complications caused by COVID-19. Study design and methods This multicentric prospective clinical trial seeks to evaluate the efficacy of bilateral lung LD-RT therapy as a treatment for interstitial pneumonia in patients with COVID-19 for improving respiratory function. This prospective study will have 2 phases: I) an exploratory phase enrolling 10 patients, which will assess the feasibility and efficacy of low-dose lung irradiation, evaluated according to an increase in the PaO2/FiO2 ratio of at least 20% at 48–72 h with respect to the pre-irradiation value. If a minimum efficiency of 30% of the patients is not achieved, the study will not be continued. II) Non-randomized comparative phase in two groups: a control group, which will only receive pharmacological treatment, and an experimental arm with pharmacological treatment and LD-RT. It will include 96 patients, the allocation will be 1: 2, that is, 32 in the control arm and 64 in the experimental arm. The primary end-point will be the efficacy of LD-RT in patients with COVID-19 pneumonia according to an improvement in PaO2/FiO2. Secondary objectives will include the safety of bilateral lung LD-RT, an improvement in the radiology image, overall mortality rates at 15 and 30 days after irradiation and characterizing anti-inflammatory mechanisms of LD-RT by measuring the level of expression of adhesion molecules, anti-inflammatory cytokines and oxidative stress mediators.
metadata.artigo.dc.identifier.uri: https://www.sciencedirect.com/science/article/pii/S2405630820300549
http://repositorio.ufla.br/jspui/handle/1/41719
metadata.artigo.dc.language: en_US
Appears in Collections:FCS - Artigos sobre Coronavirus Disease 2019 (COVID-19)

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.